Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetically Defined, Syngeneic Organoid Platform for Developing Combination Therapies for Ovarian Cancer

6 Nov 2020

Abstract excerpt

Abstract The paucity of genetically informed, immunocompetent tumor models impedes evaluation of conventional, targeted, and immune therapies. By engineering mouse fallopian tube epithelial organoids using lentiviral gene transduction and/or CRISPR/Cas9 mutagenesis, we generated multiple high-grade serous tubo-ovarian cancer (HGSC) models exhibiting mutational combinations seen in patients with HGSC. Detailed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR and Genetic Engineering
Share to Ovarian cancer diagnosis and treatment
Share to Single-cell and spatial transcriptomics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33158842
DOI: 10.1158/2159-8290.cd-20-0455

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetically Defined, Syngeneic Organoid Platform for Developing Combination Therapies for Ovarian CancerPMID 33158842Read ↗

Genetically Defined, Syngeneic Organoid Platform for Developing Combination Therapies for Ovarian CancerSemantic proximity Read ↗

Multiplex organoid mutagenesis reveals gene combinations driving transformation, pathology, and chemosensitivity in ovarian carcinoma.Semantic proximity Read ↗

Combinatorial organoid mutagenesis screen reveals gene constellations driving malignant transformation, pathology and chemosensitivity in high-grade serous ovarian carcinomaSemantic proximity Read ↗

Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.Semantic proximity Read ↗

Murine cell lines with defined mutations model different histological subtypes of epithelial ovarian cancer.Semantic proximity Read ↗

Both Fallopian Tube and Ovarian Surface Epithelium Can Act as Cell-of-Origin for High Grade Serous Ovarian CarcinomaSemantic proximity Read ↗

Both fallopian tube and ovarian surface epithelium are cells-of-origin for high-grade serous ovarian carcinoma.Semantic proximity Read ↗

Murine Oviductal High-Grade Serous Carcinomas Mirror the Genomic Alterations, Gene Expression Profiles, and Immune Microenvironment of Their Human CounterpartsSemantic proximity Read ↗

Precious GEMMs: emergence of faithful models for ovarian cancer researchSemantic proximity Read ↗

Loss of Trp53 results in a hypoactive T cell phenotype accompanied by reduced pro-inflammatory signaling in a syngeneic orthotopic mouse model of ovarian high-grade serous carcinoma.Semantic proximity Read ↗

Pathway-specific engineered mouse allograft models functionally recapitulate human serous epithelial ovarian cancer.Semantic proximity Read ↗

Comparative analysis of syngeneic mouse models of high-grade serous ovarian cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.